MYGN News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers
SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session.
Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands atread more...
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers
SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session.
Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands atread more...
Benzinga
Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed; Dow rose 400 points. Hasbro surged on strong earnings and outlook, while Braze, Myriad Genetics and others gained.read more...
Benzinga
Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln
(RTTNews) - Laboratory services provider LabCorp Holdings Inc. (LH) announced on Tuesday that it has agreed to acquire the Prenatal Health testing business of molecular diagnostics company Myriad Genetics Inc. (MYGN) for $210 million in cash, plus the value of inventory at closin...
Nasdaq News: Markets
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyPR NewswireBOSTON, Oct. 8, 2026BOSTON, Oct. 8, 2026...
PR Newswire
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (Myriad Genetics or the Company) (NASDAQ: MYGN) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other...
Business Wire
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 10, 2026 Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208...
PR Newswire
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses...
Business Wire
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA of $37 million to $49 million and adjusted gross margin of 68% to 69% for full-year 2026. Roughly three months later, the adjusted EBITDA range was suspended outright and MYGN shares dropped. If you held Myriad Genetics stock...
Business Wire